Targeting the Bcl-2-regulated apoptosis pathway by BH3 mimetics: a breakthrough in anticancer therapy?
Open Access
- 28 March 2008
- journal article
- review article
- Published by Springer Science and Business Media LLC in Cell Death & Differentiation
- Vol. 15 (6), 977-987
- https://doi.org/10.1038/cdd.2008.37
Abstract
No abstract availableKeywords
This publication has 81 references indexed in Scilit:
- The BCL-2 protein family: opposing activities that mediate cell deathNature Reviews Molecular Cell Biology, 2008
- Autocrine TNFα Signaling Renders Human Cancer Cells Susceptible to Smac-Mimetic-Induced ApoptosisCancer Cell, 2007
- Upregulation of bfl-1 is a potential mechanism of chemoresistance in B-cell chronic lymphocytic leukaemiaBritish Journal of Cancer, 2007
- Initiation of apoptosis and autophagy by the Bcl-2 antagonist HA14-1Cancer Letters, 2007
- Functional and physical interaction between Bcl-XL and a BH3-like domain in Beclin-1The EMBO Journal, 2007
- The Bcl-2 apoptotic switch in cancer development and therapyOncogene, 2007
- The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralizedCancer Cell, 2006
- Bim and Bad mediate imatinib-induced killing of Bcr/Abl + leukemic cells, and resistance due to their loss is overcome by a BH3 mimeticProceedings of the National Academy of Sciences of the United States of America, 2006
- Promoting apoptosis as a strategy for cancer drug discoveryNature Reviews Cancer, 2005
- Development of a Potent Bcl-xLAntagonist Based on α-Helix MimicryJournal of the American Chemical Society, 2002